Academic Journal
Q1International Journal of Neuropsychopharmacology
About International Journal of Neuropsychopharmacology
About International Journal of Neuropsychopharmacology
International Journal of Neuropsychopharmacology is a peer-reviewed scholarly journal published by Oxford University Press (United Kingdom). It focuses on Q1. Publication coverage spans 1998-2026.
Key indicators: ISSN 1461-1457, 1469-5111; H-index 135.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (135): Exceptionally high — 135 articles have each been cited at least 135 times. This indicates deep, sustained influence in the field.
Publishing in International Journal of Neuropsychopharmacology
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of International Journal of Neuropsychopharmacology?
1461-1457, 1469-5111.
Who publishes International Journal of Neuropsychopharmacology?
Oxford University Press.
What are International Journal of Neuropsychopharmacology's metrics?
H-index 135.
Where do I submit to International Journal of Neuropsychopharmacology?
Via the official website.
Is International Journal of Neuropsychopharmacology peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2022-12-20. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Neurotransmitter Receptor Influence on Behavior; Tryptophan and brain disorders; Treatment of Major Depression; Schizophrenia research and treatment; Neuroscience and Neuropharmacology Research; Stress Responses and Cortisol.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Multimodal Evidence for Large-scale Network Imbalance in Etomidate Use Disorder
Juan Le, Xingmin Wang, Ying Tang, Hao Chen et al.
2026-10-14 · DOI: 10.1093/ijnp/pyag049Disruption of ultrasonic vocalizations with systemic administration of the non-competitive N-methyl-D-aspartate receptor antagonist MK-801 in adult male mice
Ryuto Tamura, Mizuki Yamamoto, Yusuke Ujihara, Haruki Kasahara et al.
2026-10-08 · DOI: 10.1093/ijnp/pyag048386. Comparative efficacy of EEG-based neurofeedback as an alternative or adjunct to pharmacological treatment in patients with ADHD and psychiatric comorbidities
AJ Ballinas Reyes
2026-09-09 · DOI: 10.1093/ijnp/pyag040.279388. Influence of dysmenorrhea on anxiety and depression in women: aspect from age, menarche, and parity
S-J Chen
2026-09-09 · DOI: 10.1093/ijnp/pyag040.060744. Discovery and Preclinical Development of a Novel Muscarinic M4 Ago-PAM for the Treatment of Schizophrenia
W Wen, P Beckett, M Lewis, D Chalmers et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.397824. Urticaria Associated with Polypharmacy Involving Quetiapine and Vortioxetine - A Case Report
F Putri, K Runtuk
2026-09-09 · DOI: 10.1093/ijnp/pyag040.413557. ECT-induced effects on brain structure, brain connectivity and cerebrospinal-fluid-based markers – a preliminary analysis
P Baldinger-Melich, S Riessland, B Spurny-Dworak, G Dörl et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040188. A single high-dose acute injection of 5-MeO-DMT reverses stress-induced anhedonia in rats
S Socolow, B Richardson, S Nasini, M Lopez-Canul et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.189495. Differential effects of social and non-social chronic stress on mPFC activity during cognitive processing
L Dornela Godoy, F Alves Verza, G Wegener, F Villela Gomes et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.079593. Regulatory mechanism of astrocytic glutamine synthetase expression
M Terunuma, Y Nasu
2026-09-09 · DOI: 10.1093/ijnp/pyag040.099853. Next-generation seizure therapy: Balancing efficacy and cognition with optimized waveforms and personalized targeting
Z-D Deng
2026-09-09 · DOI: 10.1093/ijnp/pyag040.508339. Brexpiprazole for emerging psychosis in an adolescent female with Asperger-type autism: a single-case clinical evaluation
F Putri, K Runtuk
2026-09-09 · DOI: 10.1093/ijnp/pyag040.256360. Machine learning-based classification of adult attention-deficit/hyperactivity disorder using cortical structural features
R-A Lin, C-Y Cheng, SS-F Gau
2026-09-09 · DOI: 10.1093/ijnp/pyag040.054640. Antidepressants engage estrogen receptor alpha and its intracellular signaling components
S Arjmand, M Rezaei, D Sardella, C Cecchi Kaadt et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.111174. AI-based neuroanatomical prediction of cytokine profiles in schizophrenia: linking peripheral inflammation to central receptor expression
N Sirbu, S M Ortega, T Pollak, N Koutsouleris et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.146427. Cardiovascular mortality and depression: a systematic review and meta-analysis of the association with antidepressant treatment and co-morbidity
T da Silva Costa, B Hall, S Hill, R Teama et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.06836. Korean longitudinal study on digitally optimized mental healthcare: a cohort profile
J Lee, J Lee, T Kim, T Choi et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.173300. Delta-9-tetrahydrocannabinol (THC) alleviates neuropathic pain and insomnia through activation of the reticular thalamus
M Lopez-Canul, A Oveisi, M L Vigano, L Posa et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.149487. Genome-wide DNA methylation analysis reveals epigenetic signatures of early life stress in major depressive disorder patients
Y Dwivedi
2026-09-09 · DOI: 10.1093/ijnp/pyag040.32760. Polygenic risk score analyses of major psychiatric disorders in association with premenstrual dysphoric disorder in patients with bipolar disorder
M J Choi, H J Lee, E Y Cho, E H Jang et al.
2026-09-09 · DOI: 10.1093/ijnp/pyag040.179Reviews
Community Reviews
Version History
October 9, 2026 at 7:08 pm
September 25, 2026